HRP20201250T1 - Topikalni pripravci koji sadrže kortikosteroid i retinoid namijenjeni liječenju psorijaze - Google Patents
Topikalni pripravci koji sadrže kortikosteroid i retinoid namijenjeni liječenju psorijaze Download PDFInfo
- Publication number
- HRP20201250T1 HRP20201250T1 HRP20201250TT HRP20201250T HRP20201250T1 HR P20201250 T1 HRP20201250 T1 HR P20201250T1 HR P20201250T T HRP20201250T T HR P20201250TT HR P20201250 T HRP20201250 T HR P20201250T HR P20201250 T1 HRP20201250 T1 HR P20201250T1
- Authority
- HR
- Croatia
- Prior art keywords
- accordance
- topical pharmaceutical
- pharmaceutical preparation
- intended
- preparation intended
- Prior art date
Links
- 230000000699 topical effect Effects 0.000 title claims 11
- 201000004681 Psoriasis Diseases 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title claims 2
- 239000003246 corticosteroid Substances 0.000 title 1
- 150000004492 retinoid derivatives Chemical class 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 239000003921 oil Substances 0.000 claims 5
- -1 dicarboxylic acid ester Chemical class 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims 3
- 239000007764 o/w emulsion Substances 0.000 claims 3
- 229960000565 tazarotene Drugs 0.000 claims 3
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 claims 3
- 229950008396 ulobetasol propionate Drugs 0.000 claims 3
- 239000000839 emulsion Substances 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 1
- 229940059904 light mineral oil Drugs 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (10)
1. Topikalni farmaceutski pripravak namijenjen upotrebi u liječenju psorijaze, naznačen time što pripravak sadrži:
(a) halobetazol-propionat u koncentraciji od 0,005-0,03 posto težine pripravka;
(b) tazaroten u koncentraciji od 0,005-0,049 posto težine pripravka; i
(c) dermatološki prihvatljivi nosač.
2. Topikalni farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što sadrži:
(a) halobetazol-propionat u koncentraciji od 0,01 posto težine pripravka; i
(b) tazaroten u koncentraciji od 0,045 posto težine pripravka.
3. Topikalni farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je pripravak emulzija ulja u vodi.
4. Topikalni farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što se halobetazol-propionat i tazaroten otapaju u tekućoj uljnoj komponenti emulzije ulja u vodi.
5. Topikalni farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što tekuća uljna komponenta sadrži ester dikarboksilne kiseline, ester monokarboksilne kiseline, ili njihove kombinacije.
6. Topikalni farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što se tekuću uljnu komponentu bira iz skupine koju čine ester dikarboksilne kiseline, ester monokarboksilne kiseline, njihove kombinacije, te njihove smjese.
7. Topikalni farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što uljna faza emulzije ulja u vodi sadrži tekuću uljnu komponentu, koja sadrži dietil-sebakat i lako mineralno ulje.
8. Topikalni farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što je emulzija losion.
9. Topikalni farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što je emulzija krema.
10. Topikalni farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se navedeni pripravak primjenjuje jednom dnevno u trajanju od osam tjedana.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181481P | 2015-06-18 | 2015-06-18 | |
| PCT/US2016/035991 WO2016205001A1 (en) | 2015-06-18 | 2016-06-06 | Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis |
| EP16729470.1A EP3310389B1 (en) | 2015-06-18 | 2016-06-06 | Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201250T1 true HRP20201250T1 (hr) | 2020-11-13 |
Family
ID=56131662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201250TT HRP20201250T1 (hr) | 2015-06-18 | 2020-08-10 | Topikalni pripravci koji sadrže kortikosteroid i retinoid namijenjeni liječenju psorijaze |
Country Status (20)
| Country | Link |
|---|---|
| US (7) | US10251895B2 (hr) |
| EP (1) | EP3310389B1 (hr) |
| JP (1) | JP6997624B2 (hr) |
| KR (2) | KR102643849B1 (hr) |
| CN (1) | CN108282998B (hr) |
| AU (1) | AU2016279801B2 (hr) |
| BR (1) | BR112017027332B1 (hr) |
| CA (1) | CA2988577A1 (hr) |
| CY (1) | CY1123354T1 (hr) |
| DK (1) | DK3310389T3 (hr) |
| ES (1) | ES2812451T3 (hr) |
| HR (1) | HRP20201250T1 (hr) |
| HU (1) | HUE050603T2 (hr) |
| LT (1) | LT3310389T (hr) |
| MX (1) | MX2017015990A (hr) |
| PL (1) | PL3310389T3 (hr) |
| PT (1) | PT3310389T (hr) |
| RS (1) | RS60672B1 (hr) |
| SI (1) | SI3310389T1 (hr) |
| WO (1) | WO2016205001A1 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11957753B2 (en) | 2010-11-22 | 2024-04-16 | Bausch Health Ireland Limited | Pharmaceutical formulations containing corticosteroids for topical administration |
| KR102643849B1 (ko) * | 2015-06-18 | 2024-03-07 | 밸리언트 파마슈티컬즈 노오쓰 아메리카 엘엘씨 | 건선을 치료하기 위한 코르티코스테로이드 및 레티노이드를 포함하는 국소 조성물 |
| CN108024954A (zh) * | 2015-07-13 | 2018-05-11 | 瑞迪博士实验室有限公司 | 局部用类视黄醇组合物 |
| BR112019023817A8 (pt) * | 2017-05-12 | 2022-12-06 | Bausch Health Us Llc | Composições tópicas e métodos para o tratamento de doenças da pele |
| US11311482B2 (en) * | 2017-05-12 | 2022-04-26 | Bausch Health Us, Llc | Topical compositions and methods for treating skin diseases |
| JP7065895B2 (ja) * | 2017-06-23 | 2022-05-12 | ラボラトリオス・サルバト・ソシエダッド・アノニマ | クロベタゾールの水中油型ナノエマルジョン組成物 |
| US10653656B2 (en) | 2018-04-05 | 2020-05-19 | Bausch Health Ireland Limited | Topical pharmaceutical compositions for treating skin conditions |
| EP3775116A4 (en) * | 2018-04-05 | 2022-03-23 | Bausch Health Ireland Limited | POLYMER EMULSION DISTRIBUTION SYSTEMS |
| US10945952B2 (en) | 2019-03-14 | 2021-03-16 | Crescita Therapeutics Inc. | Rinse-off compositions and uses thereof for delivery of active agents |
| KR102327827B1 (ko) | 2019-11-01 | 2021-11-18 | 한국과학기술연구원 | 강황 추출물을 유효성분으로 포함하고 자외선 처리를 포함하는 건선 개선용 조성물 |
| CN113116891B (zh) * | 2019-12-30 | 2024-07-16 | 重庆华邦制药有限公司 | 一种乳膏及其制备方法 |
| KR102527907B1 (ko) | 2020-09-14 | 2023-05-03 | 한국과학기술연구원 | 무산상자 추출물을 유효성분으로 포함하는 건선 개선용 조성물 |
| KR102451304B1 (ko) | 2020-09-14 | 2022-10-07 | 한국과학기술연구원 | 꿩의다리속 추출물을 유효성분으로 포함하는 건선 개선용 조성물 |
| KR102461001B1 (ko) | 2020-09-14 | 2022-11-01 | 한국과학기술연구원 | 술패랭이꽃 추출물을 유효성분으로 포함하는 건선 개선용 조성물 |
| KR20230041257A (ko) | 2021-09-17 | 2023-03-24 | 한국과학기술연구원 | 시미시푸고라이드 에이를 유효성분으로 포함하는 건선 개선용 조성물 |
| KR20230041255A (ko) | 2021-09-17 | 2023-03-24 | 한국과학기술연구원 | 눈개승마 추출물을 유효성분으로 포함하는 건선 개선용 조성물 |
| CN113975249B (zh) * | 2021-10-14 | 2023-01-03 | 中山大学·深圳 | Tris-BNP纳米颗粒的制备及其在皮肤疾病治疗中的应用 |
| CN113712918A (zh) * | 2021-10-28 | 2021-11-30 | 济南纽华医药科技有限公司 | 一种阿普斯特微乳及其制备方法 |
| WO2024141639A1 (en) * | 2022-12-31 | 2024-07-04 | Bausch Health Ireland Limited | Use of a fixed combination of halobetasol propionate and tazarotene to treat conditions mediated by interleukin-17a |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU75903A1 (hr) | 1976-09-29 | 1978-05-16 | ||
| NL7105591A (en) | 1971-04-24 | 1972-10-26 | Topical antiphlogistic compsns - contng 3, 20-diketo-9 alpha, 11 beta-dichloro - 16 alpha, 17 alpha-dimethyl-21-hydroxy pregna-1,4- | |
| DE2655570A1 (de) | 1975-12-12 | 1977-06-16 | Ciba Geigy Ag | Neue polyhalogensteroide und verfahren zu ihrer herstellung |
| US4048310A (en) | 1976-02-24 | 1977-09-13 | E. R. Squibb & Sons, Inc. | Topical steroid formulation in form of lotion or cream |
| US4083974A (en) | 1977-03-07 | 1978-04-11 | The Upjohn Company | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether |
| JPS5850964B2 (ja) | 1978-03-07 | 1983-11-14 | 東興薬品工業株式会社 | ステロイド含有クリ−ム製剤およびその製造方法 |
| US4299828A (en) | 1979-05-31 | 1981-11-10 | E. R. Squibb & Sons, Inc. | Corticosteroid stick formulations |
| AU5794680A (en) | 1979-05-31 | 1980-12-04 | E.R. Squibb & Sons, Inc. | Corticosteroid stick formulations |
| US4233295A (en) | 1979-05-31 | 1980-11-11 | E. R. Squibb & Sons, Inc. | Corticosteroid formulations containing sebacate carrier |
| CH649923A5 (de) | 1980-10-06 | 1985-06-28 | Glaxo Group Ltd | Topisch verabreichbare pharmazeutische zusammensetzungen, enthaltend anti-inflammatorische steroide. |
| JPS58225009A (ja) | 1982-06-23 | 1983-12-27 | Shionogi & Co Ltd | コルチコステロイド外用製剤 |
| DE3225848A1 (de) | 1982-07-07 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | Kortikoidhaltige zubereitung zur topischen applikation |
| GB8401965D0 (en) | 1984-01-25 | 1984-02-29 | Beecham Group Plc | Composition |
| CA1303991C (en) | 1986-03-31 | 1992-06-23 | Chung H. Cheng | Composition and method for delivering a steroid active ingredient |
| US5019569A (en) | 1986-11-03 | 1991-05-28 | Ortho Pharmaceutical Corporation | Reversal of glucocorticoid-induced skin atrophy |
| JPH0676327B2 (ja) | 1987-04-14 | 1994-09-28 | 株式会社大塚製薬工場 | ステロイド軟膏製剤 |
| JPH0676328B2 (ja) | 1987-04-14 | 1994-09-28 | 株式会社大塚製薬工場 | ステロイドクリ−ム製剤 |
| JPH07116026B2 (ja) | 1987-07-07 | 1995-12-13 | 株式会社資生堂 | ジクロフェナックナトリウム含有乳化外用剤 |
| US5422361A (en) | 1989-12-20 | 1995-06-06 | Schering Corporation | Stable cream and lotion bases for lipophilic drug compositions |
| JP3340126B2 (ja) | 1990-03-02 | 2002-11-05 | 株式会社資生堂 | 非ステロイド系消炎鎮痛薬を含む水中油型乳化組成物 |
| US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| TW218849B (hr) * | 1991-05-17 | 1994-01-11 | Bristol Myers Squibb Co | |
| EP0969847A1 (en) | 1997-02-20 | 2000-01-12 | Allergan Sales, Inc. | Tazarotene and corticosteroid treatment for psoriasis |
| SE9800729L (sv) | 1998-03-06 | 1999-09-07 | Scotia Lipidteknik Ab | Ny topikal formulering I |
| GB9823036D0 (en) | 1998-10-22 | 1998-12-16 | Glaxo Group Ltd | Fluticasone lotion having improved vasoconstrictor activity |
| AU2877800A (en) * | 1999-02-12 | 2000-08-29 | Susan Bershad | Short contact treatment of psoriasis with topical retinoids |
| US6730308B1 (en) * | 1999-03-08 | 2004-05-04 | Allergan, Inc. | Tazarotene and alpha hydroxy acid treatment for psoriasis and/or photodamage |
| US6656928B1 (en) | 1999-09-02 | 2003-12-02 | Mccadden Michael E. | Composition for the topical treatment of rashes, dermatoses and lesions |
| US6479058B1 (en) | 1999-09-02 | 2002-11-12 | Mccadden Michael E. | Composition for the topical treatment of poison ivy and other forms of contact dermatitis |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| MXPA03003511A (es) * | 2000-10-27 | 2004-05-04 | Leo Pharma As | Composicion topica que contiene al menos una vitamina d o un analogo de vitamina de y al menos un corticosteroide. |
| US6709663B2 (en) | 2001-08-31 | 2004-03-23 | Healthpoint, Ltd. | Multivesicular emulsion drug delivery systems |
| US6765001B2 (en) | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
| US7544674B2 (en) | 2002-10-25 | 2009-06-09 | Galderma S.A. | Topical skin care composition |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| CN1210034C (zh) * | 2002-12-06 | 2005-07-13 | 重庆华邦制药股份有限公司 | 治疗银屑病的药物组合物 |
| AU2003302305A1 (en) | 2002-12-31 | 2004-07-22 | Sachin S Bhagwat | Benzoquinolizine-2-carboxylic acid-containing compositions |
| JP2004359585A (ja) | 2003-06-03 | 2004-12-24 | Medorekkusu:Kk | 被膜形成型の副腎皮質ステロイド薬含有外用製剤 |
| CN1210041C (zh) * | 2003-09-29 | 2005-07-13 | 中国医学科学院皮肤病研究所 | 治疗痤疮的复方外用药物 |
| CN1210035C (zh) * | 2003-09-29 | 2005-07-13 | 中国医学科学院皮肤病研究所 | 治疗银屑病的复方外用药物 |
| US8741333B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
| JPWO2006098353A1 (ja) | 2005-03-15 | 2008-08-28 | 協和醗酵工業株式会社 | 外用剤 |
| TW200740441A (en) | 2005-06-17 | 2007-11-01 | Combinatorx Inc | Methods and reagents for the treatment of inflammatory disorders |
| JP2009519956A (ja) | 2005-12-14 | 2009-05-21 | ザーズ， インコーポレイテッド | 薬物の皮膚送達のための組成物および方法 |
| WO2008038147A2 (en) | 2006-07-05 | 2008-04-03 | Foamix Ltd. | Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof |
| WO2008152444A2 (en) | 2006-11-29 | 2008-12-18 | Foamix Ltd. | Foamable waterless compositions with modulating agents |
| WO2009063493A2 (en) | 2007-09-10 | 2009-05-22 | Glenmark Pharmaceuticals Limited | Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid |
| WO2009084020A2 (en) | 2007-10-18 | 2009-07-09 | Glenmark Pharmaceuticals Limited | Topical composition comprising halobetasol and salicylic acid |
| KR102080429B1 (ko) | 2008-06-26 | 2020-02-21 | 안테리오스, 인코퍼레이티드 | 경피 운반 |
| JP6130992B2 (ja) | 2009-02-25 | 2017-05-17 | スティーフェル リサーチ オーストラリア ピーティーワイ リミテッド | 局所用フォーム組成物 |
| US20130310355A1 (en) | 2009-12-15 | 2013-11-21 | Young Pharmaceuticals, Inc. | Low toxicity topical active agent delivery system |
| US9782341B2 (en) | 2010-10-15 | 2017-10-10 | John E. Kulesza | Delivery of hydrophobic bioactive agents |
| CN107308163A (zh) * | 2010-11-04 | 2017-11-03 | 442合资有限责任公司 | 用于治疗皮肤病的组合物和方法 |
| US8809307B2 (en) | 2010-11-22 | 2014-08-19 | Dow Pharmaceutical Sciences, Inc. | Pharmaceutical formulations containing corticosteroids for topical administration |
| US9034926B2 (en) * | 2010-12-30 | 2015-05-19 | Nicholas V. Perricone | Topical nitrone spin trap compositions for psoriasis |
| WO2012167018A1 (en) | 2011-06-03 | 2012-12-06 | Allergan, Inc. | Targeted delivery of retinoid compounds to the sebaceous glands |
| SG11201403762PA (en) | 2012-01-09 | 2014-07-30 | Almirall Sa | Topical pharmaceutical compositions comprising bexarotene and a corticosteroids |
| US20140112959A1 (en) | 2012-10-18 | 2014-04-24 | MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite | Topical steroid composition and method |
| CN104288157B (zh) * | 2013-01-29 | 2018-04-13 | 江苏知原药业有限公司 | 包含丙酸氯倍他索和维a酸的固体分散体及其制备方法 |
| WO2015044857A1 (en) * | 2013-09-25 | 2015-04-02 | Ranbaxy Laboratories Limited | Topical spray composition of halobetasol |
| KR102643849B1 (ko) | 2015-06-18 | 2024-03-07 | 밸리언트 파마슈티컬즈 노오쓰 아메리카 엘엘씨 | 건선을 치료하기 위한 코르티코스테로이드 및 레티노이드를 포함하는 국소 조성물 |
| US20190133943A1 (en) | 2015-06-18 | 2019-05-09 | Valeant Pharmaceuticals North America | Topical compositions and methods for treating skin diseases |
| BR112019023817A8 (pt) | 2017-05-12 | 2022-12-06 | Bausch Health Us Llc | Composições tópicas e métodos para o tratamento de doenças da pele |
| US11311482B2 (en) * | 2017-05-12 | 2022-04-26 | Bausch Health Us, Llc | Topical compositions and methods for treating skin diseases |
-
2016
- 2016-06-06 KR KR1020187001229A patent/KR102643849B1/ko active IP Right Grant
- 2016-06-06 LT LTEP16729470.1T patent/LT3310389T/lt unknown
- 2016-06-06 SI SI201630936T patent/SI3310389T1/sl unknown
- 2016-06-06 BR BR112017027332-2A patent/BR112017027332B1/pt active IP Right Grant
- 2016-06-06 JP JP2017563568A patent/JP6997624B2/ja active Active
- 2016-06-06 EP EP16729470.1A patent/EP3310389B1/en active Active
- 2016-06-06 CN CN201680035629.7A patent/CN108282998B/zh active Active
- 2016-06-06 KR KR1020247006984A patent/KR20240035898A/ko active Search and Examination
- 2016-06-06 HU HUE16729470A patent/HUE050603T2/hu unknown
- 2016-06-06 PL PL16729470T patent/PL3310389T3/pl unknown
- 2016-06-06 RS RS20200997A patent/RS60672B1/sr unknown
- 2016-06-06 CA CA2988577A patent/CA2988577A1/en active Pending
- 2016-06-06 PT PT167294701T patent/PT3310389T/pt unknown
- 2016-06-06 US US15/173,961 patent/US10251895B2/en active Active
- 2016-06-06 MX MX2017015990A patent/MX2017015990A/es active IP Right Grant
- 2016-06-06 DK DK16729470.1T patent/DK3310389T3/da active
- 2016-06-06 WO PCT/US2016/035991 patent/WO2016205001A1/en active Application Filing
- 2016-06-06 AU AU2016279801A patent/AU2016279801B2/en active Active
- 2016-06-06 ES ES16729470T patent/ES2812451T3/es active Active
-
2018
- 2018-02-23 US US15/903,785 patent/US10426787B2/en active Active
-
2019
- 2019-04-08 US US16/377,540 patent/US20190231797A1/en not_active Abandoned
-
2020
- 2020-08-04 CY CY20201100719T patent/CY1123354T1/el unknown
- 2020-08-10 HR HRP20201250TT patent/HRP20201250T1/hr unknown
-
2021
- 2021-01-21 US US17/154,591 patent/US11679115B2/en active Active
- 2021-07-02 US US17/366,871 patent/US11679116B2/en active Active
-
2022
- 2022-11-23 US US17/993,817 patent/US11648256B2/en active Active
-
2023
- 2023-05-04 US US18/312,162 patent/US20230355640A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201250T1 (hr) | Topikalni pripravci koji sadrže kortikosteroid i retinoid namijenjeni liječenju psorijaze | |
| JP2018526325A5 (hr) | ||
| FR3024037B1 (fr) | Ingredient actif cosmetique ou dermatologique comprenant un melange d'acides dicarboxyliques gras insatures, compositions le comprenant et utilisations cosmetiques ou dermatologiques | |
| ITUB20153106A1 (it) | Composizione di batteri lattici per uso nel trattamento delle infezioni causate da Propionibacterium acnes e in particolare per l'acne | |
| CL2016001777A1 (es) | Composición herbicida que contiene ácido 4-amino-3-cloro-6-(4-cloro-2-fluoro-3-metoxifenil) piridin-2-carboxílico o sus derivados, fluroxipir o sus derivados y fenoxiauxinas o sus derivados | |
| BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
| MA43918A (fr) | Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 | |
| BR112017024940A2 (pt) | composições de óleo essencial e seu método | |
| RU2018109969A (ru) | Экстракт гардении для окрашивания кожи | |
| ITUB20153130A1 (it) | Acidi grassi cetilati, impianto per la loro preparazione e relativo uso | |
| WO2017106367A8 (en) | Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity | |
| WO2017132445A8 (en) | Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor | |
| BR112015001989A2 (pt) | composição farmacêutica para inibir a autofagia de neurônios motores e uso da mesma | |
| EA201790116A1 (ru) | Масло семян коикса, содержащее 13 глицеридов, его препарат и их применение | |
| CL2014001833A1 (es) | Uso de cascaras de palta con el fin de obtener un insaponificable de palta enriquecido en hidrocarburos alifaticos saturados y en esteroles, donde las cascaras representan del 5 al 50% en peso en relacion al peso total de las paltas utilizadas; metodo para obtener un insaponificable de palta; y dicho producto. | |
| BR112018010928A2 (pt) | método de tratamento de uma corrente, e, líquido de desempenho multicomponente | |
| CL2018001200A1 (es) | Emulsión de gas en aceite en agua y método para su preparación. | |
| AR119193A2 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| TH168845A (th) | สารองค์ประกอบไขน้ำมันสำหรับแป้งนวดของจำพวกเส้นบะหมี่และไขน้ำมันสำหรับ แป้งนวดของจำพวกเส้นบะหมี่และวิธีผลิตจำพวกเส้นบะหมี่ | |
| ES2575127B2 (es) | Mercaptoftalocianinas, procedimiento de preparación de las mismas y su anclaje a nanopartículas metálicas | |
| TH162758A (th) | องค์ประกอบที่ใช้สำหรับช่องปาก | |
| TH162758B (th) | องค์ประกอบที่ใช้สำหรับช่องปาก | |
| TH168845B (th) | สารองค์ประกอบไขน้ำมันสำหรับแป้งนวดของจำพวกเส้นบะหมี่และไขน้ำมันสำหรับ แป้งนวดของจำพวกเส้นบะหมี่และวิธีผลิตจำพวกเส้นบะหมี่ | |
| WO2016196256A3 (en) | Non-aromatic difluoro analogues of resorcylic acid lactones | |
| FI20166034A (fi) | Polttoainekoostumuksen valmistaminen |